Prasugrel vs. Ticagrelor for Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.
Muhammad Shahzeb KhanMuhammad Mustafa MemonMuhammad Shariq UsmanSaed AlnaimatSafi U KhanAbdur Rahman KhanNaser YamaniSetri FugarFarouk MookadamRichard A KrasuskiRami DoukkyPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2020)
The present analysis suggests that prasugrel might have a better efficacy profile than ticagrelor in patients with ACS undergoing PCI. However, this advantage was only seen in pooled observational studies and is likely to be affected by selection bias.
Keyphrases
- percutaneous coronary intervention
- acute coronary syndrome
- st segment elevation myocardial infarction
- antiplatelet therapy
- st elevation myocardial infarction
- acute myocardial infarction
- patients undergoing
- coronary artery bypass grafting
- coronary artery bypass
- coronary artery disease
- heart failure
- randomized controlled trial
- atrial fibrillation